Intellia Therapeutics, Inc. (NASDAQ:NTLA) Expected to Announce Quarterly Sales of $10.34 Million

Wall Street analysts predict that Intellia Therapeutics, Inc. (NASDAQ:NTLAGet Rating) will report $10.34 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for Intellia Therapeutics’ earnings, with the highest sales estimate coming in at $17.50 million and the lowest estimate coming in at $5.70 million. Intellia Therapeutics posted sales of $6.45 million during the same quarter last year, which suggests a positive year over year growth rate of 60.3%. The firm is scheduled to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Intellia Therapeutics will report full year sales of $48.24 million for the current financial year, with estimates ranging from $5.03 million to $145.80 million. For the next year, analysts expect that the company will post sales of $42.96 million, with estimates ranging from $5.50 million to $120.00 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last announced its earnings results on Thursday, February 24th. The company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by ($0.18). The firm had revenue of $12.90 million during the quarter, compared to analysts’ expectations of $7.83 million. Intellia Therapeutics had a negative net margin of 810.49% and a negative return on equity of 33.61%. The company’s revenue was up 95.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.69) EPS.

A number of equities research analysts recently issued reports on the company. Brookline Capital Management raised Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $91.00 price target for the company in a research note on Monday, March 7th. Chardan Capital cut their price target on shares of Intellia Therapeutics from $177.00 to $172.00 and set a “buy” rating on the stock in a report on Tuesday, March 1st. William Blair initiated coverage on shares of Intellia Therapeutics in a report on Friday, February 18th. They set an “outperform” rating and a $144.00 price objective for the company. Oppenheimer upgraded shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $145.00 to $150.00 in a research note on Monday, February 7th. Finally, Piper Sandler initiated coverage on shares of Intellia Therapeutics in a research note on Friday, January 7th. They set an “overweight” rating and a $171.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Buy” and an average price target of $149.74.

Shares of NASDAQ:NTLA traded down $1.76 during trading hours on Friday, hitting $61.24. 23,008 shares of the company’s stock traded hands, compared to its average volume of 1,155,924. The business has a fifty day moving average price of $78.83 and a 200-day moving average price of $104.86. Intellia Therapeutics has a 1 year low of $56.47 and a 1 year high of $202.73.

Several large investors have recently added to or reduced their stakes in the company. Morgan Stanley boosted its position in shares of Intellia Therapeutics by 38.1% in the 2nd quarter. Morgan Stanley now owns 697,723 shares of the company’s stock worth $112,968,000 after purchasing an additional 192,393 shares in the last quarter. Wolff Wiese Magana LLC boosted its holdings in Intellia Therapeutics by 21.5% in the third quarter. Wolff Wiese Magana LLC now owns 1,464 shares of the company’s stock worth $196,000 after acquiring an additional 259 shares in the last quarter. Strs Ohio grew its stake in shares of Intellia Therapeutics by 4.3% during the third quarter. Strs Ohio now owns 17,000 shares of the company’s stock worth $2,280,000 after acquiring an additional 700 shares during the last quarter. Spire Wealth Management increased its holdings in shares of Intellia Therapeutics by 125.0% during the third quarter. Spire Wealth Management now owns 450 shares of the company’s stock valued at $60,000 after acquiring an additional 250 shares in the last quarter. Finally, Capital Advisors Inc. OK raised its position in shares of Intellia Therapeutics by 2,006.9% in the 3rd quarter. Capital Advisors Inc. OK now owns 44,245 shares of the company’s stock valued at $5,935,000 after purchasing an additional 42,145 shares during the last quarter. Institutional investors and hedge funds own 86.60% of the company’s stock.

Intellia Therapeutics Company Profile (Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Featured Articles

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.